Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Issue 12 (21st November 2003)

• Record Type: Journal Article
• Authors: Keller, C; Webb, A; Davis, J
• Is Part Of: Annals of the rheumatic diseases. Volume 62:Issue 12(2003)
• Page Start: 1128
• Page End: 1132
• Publication Date: 2003-11-21
• Subjects: spondylitis -- cytokines -- tumour necrosis factor α; AS, ankylosing spondylitis -- BASFI, Bath Ankylosing Spondylitis Functional Index -- ELISA, enzyme linked immunosorbent assay -- ESR, erythrocyte sedimentation rate -- IFNγ, interferon gamma -- IL, interleukin -- LPLs, lamina propria lymphocytes -- MEI, Modified Enthesopathy Index -- OA, osteoarthritis -- PBMCs, peripheral blood mononuclear cells -- PMA, phorbol myristate acetate -- PsA, psoriatic arthritis -- RA, rheumatoid arthritis -- RT-PCR, reverse transcriptase-polymerase chain reaction -- SpA, spondyloarthropathies -- TGF, transforming growth factor -- TNF, tumour necrosis factor; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2003.011023
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Rheumatoid arthritis (RA) is a disease well characterised by proinflammatory cytokine secretion (particularly tumour necrosis factor, interferon gamma, interleukin (IL) 1, and IL6). Less has been reported about the cytokine profiling in the spondyloarthropathies (SpA). Several trials suggest that, similar to RA, proinflammatory cytokines are globally expressed in the SpA. However, other studies report a down regulation of these cytokines in the SpA, with a relative anti-inflammatory polarisation (featuring increases in IL4, IL5, and IL10). This review summarises current published reports and the variation in cytokine data in the SpA. Additionally, results of cytokine profiles in patients with ankylosing spondylitis before and after treatment with etanercept are reported.